These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Corpus cavernosum injection treatment of erectile impotence]. Lenk S; Schönherr G; Korner I Z Urol Nephrol; 1990 Oct; 83(10):539-46. PubMed ID: 2095661 [TBL] [Abstract][Full Text] [Related]
25. [Normal prolactin values in a group of patients with idiopathic erectile impotence: preliminary observations]. Chiodera P; Volpi R; Valenti G; Legros JJ G Clin Med; 1980 Jul; 61(7):530-4. PubMed ID: 6450075 [No Abstract] [Full Text] [Related]
26. [Drugs for impotence]. Lukkarinen O; Pelkonen R Duodecim; 1995; 111(8):771-6. PubMed ID: 8681837 [No Abstract] [Full Text] [Related]
27. [Prostaglandin E1 in erectile dysfunction]. Porst H Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258 [TBL] [Abstract][Full Text] [Related]
28. The use of prostaglandins for diagnosis and treatment of erectile impotence. Merckx L; Vanwaeyenbergh J; De Bruyne R; Braeckman J; Keuppens F Acta Urol Belg; 1991; 59(3):47-52. PubMed ID: 1759665 [TBL] [Abstract][Full Text] [Related]
29. Relation between intracavernosal dose of prostaglandin Pge 1 and mean duration of erection in men with different underlying causes of erectile dysfunction. Bratus D; Hlebic G; Hajdinjak T Croat Med J; 2007 Feb; 48(1):76-80. PubMed ID: 17309142 [TBL] [Abstract][Full Text] [Related]
30. [Intracavernous injection of papaverine hydrochloride for impotence in patients with spinal cord injury]. Momose H; Natsume O; Yamamoto M; Suemori T; Yamada K Hinyokika Kiyo; 1987 Jul; 33(7):1065-9. PubMed ID: 3687629 [TBL] [Abstract][Full Text] [Related]
31. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents. Kiely EA; Bloom SR; Williams G Br J Urol; 1989 Aug; 64(2):191-4. PubMed ID: 2765789 [TBL] [Abstract][Full Text] [Related]
32. Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence. Kattan S; Collins JP; Mohr D Urology; 1991 Jun; 37(6):516-8. PubMed ID: 2038782 [TBL] [Abstract][Full Text] [Related]
33. [Classification of patterns of nocturnal penile tumescence with continuous monitoring of penile rigidity: analysis of various factors affecting erection]. Yasumoto R; Kawano M; Tsurusaki K; Yoneda Y; Ishii K; Khono T; Kumata N; Fukui J; Hayashi S; Tsujino T; Umeda M Hinyokika Kiyo; 1996 Apr; 42(4):285-8. PubMed ID: 8693961 [TBL] [Abstract][Full Text] [Related]
34. [Hypothalamo-hypophyseo-gonadal axis in individuals with chronic renal insufficiency subjected to hemodialysis]. Mendoza C; Carreras A; Ruiz E; Ortega E; Hervás J; Osorio C Rev Esp Fisiol; 1985 Dec; 41(4):443-6. PubMed ID: 3938041 [TBL] [Abstract][Full Text] [Related]
35. Penile prosthesis surgery in the immunosuppressed patient. Hill CC; Jordon ML; Bahnson RR Transplantation; 1993 Oct; 56(4):1020-1. PubMed ID: 7692633 [No Abstract] [Full Text] [Related]
37. [Possibilities of treatment of erectile disorders by the administration of vasoactive substances into the penis using iontophoresis]. Babula V; Sedmík J; Zvĕrina J Cas Lek Cesk; 1989 Oct; 128(43-44):1367-8. PubMed ID: 2598251 [TBL] [Abstract][Full Text] [Related]
38. Prostaglandin E1 in the medical management of erectile dysfunction in a genito-urinary medicine clinic. Armstrong DK; Convery A; Dinsmore WW Ulster Med J; 1994 Apr; 63(1):18-22. PubMed ID: 8658990 [TBL] [Abstract][Full Text] [Related]
39. Treatment of prolonged or priapistic erections following intracavernosal papaverine therapy. Padma-Nathan H; Goldstein I; Krane RJ Semin Urol; 1986 Nov; 4(4):236-8. PubMed ID: 3797893 [No Abstract] [Full Text] [Related]
40. [Treatment of sexual impotency by intra-cavernous injections of prostaglandin E1. Report of 180 patients]. Amar E; Kobelinsky M; Khoury R; Sarkis P; Bouyer I; Dauphin A; Delmas V; Boccon-Gibod L Prog Urol; 1993 Dec; 3(6):971-8. PubMed ID: 8305940 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]